Evidence map›Paper›PMID 23974982›Full record

ReviewLeukemia2014

IMWG consensus on risk stratification in multiple myeloma.

W J Chng, A Dispenzieri, C-S Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, J S Miguel, P Sonneveld and 5 more

Registry-linked trialAbstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03421132 (The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study), which is not on this map. Cited by 301 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
301citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03421132 active not recruitingnot on this mapstarted 2018, after this paper: background citation

The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study

TypeobservationalSponsorHorizon Health NetworkRan2018 to 2026Enrolled96ConditionsMultiple Myeloma
3 · Its place in the literature

Who cites it

301 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

241 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

W J Chng1] Department of Haematology Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore [2] Experimental Therapeutics, Cancer Science Institute of Singapore, Singapore, Singapore [3] Department of Medicine, Yoo Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
A DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
C-S ChimDivision of Hematology and Medical Oncology, Queen Mary Hospital, Hong, Kong.
R FonsecaDivision of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
H GoldschmidtUniversity of Heidelberg, Heidelberg, Germany.
S LentzschDepartment of Medicine, Hematology/Oncology, Columbia University, NY, USA.
N MunshiDana- Farber Cancer Institute, Boston, MA, USA.
A PalumboMyeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
J S MiguelServicio de Hematologia, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain.
P SonneveldDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
M CavoInstitute of Hematology and Medical Oncology "Seragnoli", Bologna University School of Medicine, Bologna, Italy.
S UsmaniMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
B G M DurieSouthwest Oncology Group, International Myeloma Foundation, Cedars- Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer, Institute, Los Angeles, CA, USA.
H Avet-LoiseauUnité de Génomique du Myélome, University Hospital, Toulouse, France.
International Myeloma Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.

Indexed as

Consensus Statements as TopicHumansMultiple MyelomaPrognosis

Identifiers

PMID23974982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.